10-KPeriod: FY2014

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2014

Filed February 13, 2015For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) reported its 2014 annual results, highlighting significant progress in its cystic fibrosis (CF) pipeline, particularly with KALYDECO and the upcoming submission for lumacaftor/ivacaftor. While KALYDECO sales showed continued growth, the company's overall revenue declined due to the winding down of its Hepatitis C (HCV) franchise, specifically the INCIVEK product. The company experienced a substantial net loss, primarily driven by ongoing research and development investments and prior year impairment charges. Key investor focus remains on the potential approval and commercial launch of the lumacaftor/ivacaftor combination therapy, expected in mid-2015, which targets a significant unmet need in CF patients with the F508del mutation. Vertex is also advancing its next-generation CFTR corrector compounds and exploring opportunities in oncology and neurology, aiming to diversify its pipeline.

Financial Highlights

49 data points
Beta

Revenue

$580.41M

93.2% Gross Margin

Net Income

-$738.55M

-127.2% Net Margin

EPS (Diluted)

$-3.14

Total Assets

$2.33B

Cash & Equivalents

$625.26M

Free Cash Flow

-$624.31M

Financial Statements
Beta
Revenue$580.41M
Cost of Revenue$39.73M
Gross Profit$540.69M
R&D Expenses$855.51M
SG&A Expenses$305.41M
Operating Expenses$1.27B
Operating Income-$692.41M
Net Income-$738.55M
EPS (Basic)$-3.14
EPS (Diluted)$-3.14
Shares Outstanding (Basic)235.31M
Shares Outstanding (Diluted)235.31M

Key Highlights

  • 1KALYDECO (ivacaftor) sales continued to grow, reaching $463.8 million in 2014, driven by label expansions and increased patient access.
  • 2Vertex submitted New Drug Applications (NDAs) and Marketing Authorization Applications (MAAs) for lumacaftor in combination with ivacaftor in November 2014, targeting patients with two copies of the F508del mutation in the CFTR gene. FDA review has a target completion date of July 5, 2015.
  • 3The company reported a net loss of $738.6 million for 2014, a significant increase from the prior year, largely due to ongoing R&D investments and previous impairment charges.
  • 4Revenues declined by 52% in 2014 to $580.4 million, primarily due to a substantial decrease in INCIVEK product revenues ($24.1 million in 2014 vs. $466.4 million in 2013) as the company wound down its HCV business.
  • 5Vertex initiated a Phase 3 development program for VX-661 in combination with ivacaftor, expanding its pipeline of potential CF therapies.
  • 6The company continues to invest heavily in research and development, with $855.5 million spent in 2014, focusing on CF and exploring programs in oncology and neurology.
  • 7Vertex has a strong cash position with approximately $1.39 billion in cash, cash equivalents, and marketable securities as of December 31, 2014, providing resources for ongoing development and operations.

Frequently Asked Questions

Vertex's primary growth driver is its focus on cystic fibrosis (CF) treatments. KALYDECO (ivacaftor) is its currently marketed CF drug, showing strong revenue growth. The company is also on the verge of potentially launching a significant new product, lumacaftor in combination with ivacaftor, for a broader CF patient population. Beyond CF, Vertex is investing in early-stage research for oncology and neurology.

Vertex submitted an NDA to the FDA and an MAA to the EMA in November 2014 for lumacaftor in combination with ivacaftor. The FDA has granted priority review with a target decision date of July 5, 2015. If approved, Vertex expects to begin recognizing revenues from this therapy in the United States in mid-2015. This combination therapy is a key focus for the company and represents a significant potential expansion of its CF franchise.

Vertex experienced a net loss in 2014, reflecting substantial investments in R&D for its promising CF pipeline, particularly KALYDECO and the lumacaftor/ivacaftor combination. The decline in overall revenue is primarily due to the strategic decision to wind down its HCV franchise, notably the INCIVEK product. The company's financial strength is supported by a robust cash balance of approximately $1.39 billion, enabling continued investment in its pipeline while it awaits potential near-term product launches.

Vertex's future development plans in CF are centered around expanding treatment options. It is seeking approval for lumacaftor in combination with ivacaftor. Furthermore, it has initiated Phase 3 trials for VX-661 in combination with ivacaftor, targeting both homozygous and heterozygous F508del mutations. The company is also actively researching and developing next-generation CFTR corrector compounds for potential triple-combination therapies.